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As for the NIH grant review proc-
ess, opting for a version of our current 
anonymous manuscript review sys-
tem by eliminating face-to-face con-
tact of reviewers would only serve to 
widen the error bars among reviews. 
Moreover, eliminating the face-to-
face discussions of study sections 
would have no effect on decreas-
ing the submission-to-score time as 
reviews are due ?5 days before the 
study section meets. This is clearly 
not the bottleneck. So the next time 
you are hiding behind the cloak of 
manuscript reviewer anonymity, ask 
yourself if you would make these 
same comments if you were required 
to summarize them at a meeting. Bet-
ter yet, would you make them about 
your own manuscript?
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There is little doubt that the current 
NIH grant review system is not per-
fect. But this is true for any nondeter-
ministic process, including scientific 
manuscript review, content consensus 
in collaborative web environments, the 
refeering of sports events, and debates 
surrounding issues of health or edu-
cation. Any process that has broad 
ramifications and requires a frequent, 
repetitive, and community-based deci-
sion will have to be consistent and fair 
but also agile and dynamic.
Pagano argues that some NIH 
grant reviewers may resemble judges 
on the TV talent show American Idol 
(Pagano, 2006). However, the modi-
fications to NIH grant review that he 
proposes (prescreening all grant 
applications, a shorter format, a more 
general future research plan, and 
elimination of face-to-face reviewer 
study sections) may swing the pen-
dulum in the other direction, resulting 
in judgements like those on the TV 
reality show Big Brother. There are 
three primary reviewers for each NIH 
grant proposal, but usually the entire 
review panel is engaged in the discus-
sion, assessment, and final summary 
of each proposal. A diverse panel is 
critical for evaluating the scientific 
quality of the proposals, impact of the 
work, and relevance of the findings. 
If there are study sections where 
Cowellesque reviewers highjack the discussion, perpetuate negative 
comments about the application, and 
mislead the entire panel into an inap-
propriate decision, this seems to be 
a problem with the composition of 
the panel rather than with the current 
evaluation system per se. “The nasty 
reviewer” would not “always win” if the 
panel acted as a democratic board of 
conscientious reviewers. There is a 
large pool of registered NIH review-
ers and an even larger pool of quali-
fied scientists who could be recruited 
to grant review panels. Like jury duty 
and term limits on public service jobs, 
there must be a regular turn over of 
reviewers, administrators, and grant 
applications to ensure that the proc-
ess runs smoothly and consistently.
Pagano’s calculation of the annual 
cost of NIH grant review ($50 million) is 
less than 0.2% of the total NIH opera-
tional budget ($29 billion). This figure 
is less than the operating costs for a 
regular company or the percentage 
costs associated with managing large 
mutual funds, academic institutes, or 
government institutions. For example, 
the administrative costs of the Univer-
sity of California are about 4% to 5% 
of the annual operating budget of $11.4 
billion. Although I agree with Pagano 
that assembling an NIH grant applica-
tion takes significant efforts on the part 
of the principal investigator and his/her 
collaborators and requires administra-Cell 127, Novtive support, I disagree that it could take 
6 months. A good team with the right 
idea and matching expertise should be 
able to deliver a solid application within 
2–8 weeks, depending on the scope of 
the project, subject area, and investi-
gator time commitment.
Pagano proposes scaling back 
face-to-face interactions among grant 
reviewers by increasing discussions 
by phone or email and only using the 
written critiques of the primary review-
ers, unless there is a rare complica-
tion requiring a teleconference. Taking 
away the face-to-face aspect of NIH 
grant review, reducing proposal page 
limits, and relying on a limited written 
communication will, in my opinion, 
adversely affect the review process. 
It will enhance the effects of “α-domi-
nant” reviewers, introduce a bias in 
favor of large labs and research con-
sortia, and increase the error rate in 
assessment, resulting in a negative 
impact on scientific research (Marks, 
2006).
Scientific progress is not determined 
solely by “funding” and “publication” as 
Pagano claims. Funding and publica-
tion are merely byproducts of the scien-
tific discovery process and are neither 
necessary nor sufficient to ensure the 
quality of research. Often the impact of 
a new scientific technique, idea, or dis-
covery is not realized until years after 
it has been communicated. There is a 
need to accommodate diverse grant 
applications (Carnes et al., 2005) that 
seek financing for research that is 
short- or long-term, low or high risk, 
small or large scale, basic or clinical, 
and led by junior or senior investigators ember 17, 2006 ©2006 Elsevier Inc. 663
(Drazen and Ingelfinger, 2003; Kotchen 
et al., 2004). We need to avoid the blind 
use of publication counts or total fund-
ing support in prospective and retro-
spective research evaluations, includ-
ing grant reviews.
We have to collectively think of a new 
strategy to avoid the occasional resem-
blance of the NIH grant review system 
to the evaluation of amateur singers on 
American Idol (“nasty reviewer always 
wins”). However, we also need to avoid 664 Cell 127, November 17, 2006 ©2006
Many scientists and NIH adminis-
trators are convinced that the NIH 
grant review process, which was not 
designed for the current large number 
of applications and the concomitant 
low success rates, needs some urgent 
adjustments to save money and time 
for both applicants and reviewers. 
My recent Correspondence in Cell 
(Pagano, 2006) was not intended to 
provide a magic solution for fixing the 
NIH grant review process. Rather, its 
purpose was to stimulate a construc-
tive discussion. Therefore, it is not my 
intention to defend my proposal as if 
it were the only solution.
The shortcomings of NIH grant 
review (the current system or possible 
alternatives) become less problem-
atic when the NIH payline is around 
25%–30%, as it was just a few years 
ago. However, now that the payline is 
down to 9%–13% (depending on the 
different NIH institutes), faultlines are 
beginning to appear. Whereas top- 
and low-score applications are easily 
identified using a variety of methods, 
there is a strong level of subjectivity 
and luck for those applications falling 
between the 10th and 20th percen-
tile. The current number of worthwhile 
applications is higher than the number 
that can be funded. Hence, the real 
issue is money. The public, Congress, 
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the NIH, and the scientific community 
need to work together to increase the 
NIH budget as soon as possible and 
to make sure that more funds are 
directed to finance R01 grants (Man-
del and Vesell, 2006; Weinberg, 2006). 
A steady payline of around 20% would 
certainly be advantageous, balancing 
the need for funding stability with the 
requirement for high-caliber science. 
Large differences in paylines arising 
during the course of only a few years 
generate serious problems for R01 
applicants, a scenario that we have 
witnessed over the last few years. In 
fact, the support of mediocre science 
during periods of high NIH funding 
directly influences the payline during 
subsequent periods of lower budg-
ets—even when budget cuts are rela-
tively minor—because each grant is 
supported with a commitment of 4 to 
5 years. In addition to affecting indi-
vidual labs, large payline oscillations 
cause huge difficulties for academic 
institutions that grow during periods of 
good funding but then need to shrink 
in response to cuts.
Clearly, until the funding situation is 
resolved (hopefully for the best), it is 
important to discuss how to improve 
the NIH grant review process. Differ-
ent systems of peer review offer vari-
ous advantages and disadvantages. 
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I believe that shortening grant appli-
cations would represent a simple solu-
tion to save money and time. Com-
pared to other grant applications, NIH 
applications, at 25 pages, are prob-
ably the longest. Grant applications to 
the US National Science Foundation, 
The Wellcome Trust, and the Howard 
Hughes Medical Institute comprise 15, 
6, and 5 pages, respectively. Appli-
cations to government agencies in 
the UK, Australia, Canada, and Israel 
require between 8 and 15 pages. In 
most cases, review of these grants also 
differs from the NIH system. For exam-
ple, it often takes place through mail or 
email, which generally guarantees that 
the same reviewer will evaluate revised 
proposals and that his/her expertise is 
not confined to just a single study sec-
tion. Some agencies prefer to disclose 
the names of the reviewers (to dimin-
ish the possibility of inflated critiques), 
whereas others opt for an anonymous 
system (to avoid understated critiques 
of reviewers hesitant to be unfavorable 
to established or well-connected inves-
tigators). Finally, in the case of many 
agencies, compared to applications for 
new grants, those for competing grant 
renewals are simplified and much more 
retrospective than prospective (Marks, 
2006; Nurse, 2006).
I also made other suggestions 
that have found support from sev-
eral dozen colleagues and even NIH 
